Dec. 4 at 8:46 PM
$MGTX On the most recent call Zandy was asked "Maybe on the manufacturing side, you kind of alluded to this briefly, but are there any public comps out there for how to think about the value of this business on a standalone basis?" Her response was a little broken up as the transcript is unedited... "So with manufacturing for each of our partners where we're the manufacturer, because in gene therapy if you manufacture -- when we manufacture because of our FDA and global regulatory interactions, our manufacturing process, which has been built on 20, 30, different viral vectors, actually gives us a GMP process fit for commercial, right, which is very, very valuable. Now, there have been similar companies sold who don't have commercial experience. We actually have commercial license and have not done as many runs or batches or assays as we have, because we do see QC, the whole QC is validated and in-house we got commercial license and I think it's sold for around
$600 million.
